Budget impact analysis in Spanish patients with Dupuytren's contracture: Fasciectomy vs. collagenase Clostridium histolyticum

Salas-Cansado, Marina de; Cuadros, Marta; Cerro, Marta del; Arandes, José M.

doi:10.1016/j.main.2013.02.012

Cited by 17 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean cost of treatment for DC was substantially lower (~30–50%) with CCH versus fasciectomy in Spain. 16 , 22 The cost savings ranged from 29% (CCH compared with fasciectomy with no subsequent physical therapy) to 51.5% (CCH compared with fasciectomy requiring subsequent hospitalization and physical therapy). 16 Finally, cost savings in Australia were notably higher—reaching up to 64%—when treating DC with CCH instead of with fasciectomy.…”

Section: Discussionmentioning

confidence: 99%

<p>Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis</p>

Zah¹,

Pelivanovic²,

Tatovic³

et al. 2020

CEOR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

<p>Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis</p>

Zah¹,

Pelivanovic²,

Tatovic³

et al. 2020

CEOR

View full text Add to dashboard Cite

“…Bei einer Prävalenz von 0,6 bis 31,6 % in den westlichen Industrieländern [6], der sich daraus ableitenden sozioökonomischen Bedeutung der Dupuytren-Kontraktur sowie des Kostendrucks im Gesundheitswesen sind außer der medizinischen Bewertung neuer Behandlungsmethoden im Vergleich zum Goldstandard auch ökonomische Betrachtungen sinnvoll und notwendig. In den vergangenen 2 Jahren sind Kosteneffektivitätsanalysen aus verschiedenen westlichen Industrieländern publiziert worden [7][8][9][10][11] In der statistischen Analyse der Datensätze zeigten sich bei beiden Gruppen hinsichtlich der Altersverteilung (p = 0,097) sowie den präoperativen …”

Section: Einleitung ▼unclassified

Kosteneffektivität der Behandlung von Patienten mit Dupuytren-Kontraktur mit mikrobieller Collagenase Clostridium histolyticum (Xiapex®) im Vergleich zur partiellen Fasziektomie in Österreich

Neuwirth

Binter

Pipam

et al. 2016

Handchir Mikrochir plast Chir

View full text Add to dashboard Cite

show abstract

“…De Salas-Cansado et al conducted an analysis in Spanish patients to estimate the budget impact of CCH versus fasciectomy [ 13 ]. The analysis showed a difference in cost favoring CCH over fasciectomy for a typical case to be 1,030€, with a substantial difference in 3-year overall base-case budgetary impact of 8,835,750€ for fasciectomy and 3,819,591€ for CCH, suggesting that CCH can result in a substantial savings as a noninvasive outpatient procedure.…”

Section: Practical Considerationsmentioning

confidence: 99%

Postapproval Clinical Experience in the Treatment of Dupuytren's Contracture with Collagenase Clostridium Histolyticum (CCH): The First 1,000 Days

Schulze¹,

Tursi

2014

Hand (New York, N,Y.)

View full text Add to dashboard Cite

Dupuytren’s contracture is a benign fibromatosis of the palmar and digital fascia of the hand of uncertain etiology, resulting in nodules and cords beneath the skin of the palm of the hands that may lead to the development of contractures. Surgical intervention is often considered when metacarpophalangeal (MP) joint contracture is 30° or more, or when there is any degree of proximal interphalangeal (PIP) joint contracture. Collagenase clostridium histolyticum (CCH) is a nonsurgical, minimally invasive enzymatic drug indicated for the treatment of adult patients with Dupuytren’s contracture (DC) and palpable cord. CCH has been available for approximately 3.5 years, and postapproval experience indicates that the effectiveness of CCH is equivalent to or better than efficacy observed in clinical trials, as seen by lower injection rates to achieve clinical success. Postapproval experience has shown a risk-benefit profile that favors CCH for patients not indicated for surgery based on current recommendations and shows also that treating earlier-stage vs later-stage joint contracture results in significantly better outcomes on average. Postapproval surveillance reveals a safety profile similar to that observed in clinical trials. Nonserious adverse events are mainly local reactions; tendon rupture, a serious adverse event, is reported rarely in the clinical practice setting and at a lower rate than in clinical trials. Risk Evaluation and Mitigation Strategy (REMS) training is designed to mitigate benefit vs risk to achieve safe and effective use of CCH.

show abstract

Budget impact analysis in Spanish patients with Dupuytren's contracture: Fasciectomy vs. collagenase Clostridium histolyticum

Cited by 17 publications

References 23 publications

<p>Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis</p>

<p>Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis</p>

Kosteneffektivität der Behandlung von Patienten mit Dupuytren-Kontraktur mit mikrobieller Collagenase Clostridium histolyticum (Xiapex®) im Vergleich zur partiellen Fasziektomie in Österreich

Postapproval Clinical Experience in the Treatment of Dupuytren's Contracture with Collagenase Clostridium Histolyticum (CCH): The First 1,000 Days

Contact Info

Product

Resources

About